Tobacco/nicotine and endogenous brain opioids.
Smoking is a major public health problem with devastating health consequences. Although many cigarette smokers are able to quit, equal numbers of others cannot! Standard medications to assist in smoking cessation, such as nicotine replacement therapies and bupropion, are ineffective in many remaining smokers. Recent developments in the neurobiology of nicotine dependence have identified several neurotransmitter systems that may contribute to the process of smoking maintenance and relapse. These include: especially dopamine, but also norepinephrine, 5-hydroxytryptamine, acetylcholine, endogenous opioids, gamma-aminobutyric acid (GABA), glutamate, and endocannabinoids. The present review examines the limited contribution of the endogenous opioid system to the complex effects of nicotine/tobacco smoking.
Xue
Yue
Y
Department of Pharmacology, University of Michigan, Ann Arbor, MI 48109-5632, USA.
Domino
Edward F
EF
D000701:Analgesics, Opioid / Q000378:metabolism*; D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000378:metabolism*; D006801:Humans; D009538:Nicotine / Q000009:adverse effects*; D014029:Tobacco Use Disorder / Q000188:drug therapy / Q000209:etiology
D000701:Analgesics, Opioid; D009538:Nicotine